HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lapolla, A. Articles by Fedele, D. Search for Related Content PubMed PubMed Citation Articles by Lapolla, A. Articles by Fedele, D. Social Bookmarking                What's this?

Advanced Glycation End Products and Antioxidant Status in Type 2 Diabetic Patients With and Without Peripheral Artery Disease

¹ Department of Medical and Surgical Sciences, University of Padova, Padova, Italy
² Warwick Medical School, Coventry, U.K.
³ Department of Pharmacology and Anesthesiology, University of Padova, Padova, Italy

Address correspondence and reprint requests to Francesco Piarulli, MD, Medical and Surgical Sciences, University of Padova, Via dei Colli 4, 35143 Padova, Italy. E-mail: francesco.piarulli{at}unipd.it

OBJECTIVE—Advanced glycation end products (AGEs), pentosidine and malondialdehyde (MDA), are elevated in type 2 diabetic subjects with coronary and carotid angiopathy. We investigated the relationship of AGEs, MDA, total reactive antioxidant potentials (TRAPs), and vitamin E in type 2 diabetic patients with and without peripheral artery disease (PAD).

RESEARCH DESIGN AND METHODS—AGEs, pentosidine, MDA, TRAP, vitamin E, and ankle-brachial index (ABI) were measured in 99 consecutive type 2 diabetic subjects and 20 control subjects.

RESULTS—AGEs, pentosidine, and MDA were higher and vitamin E and TRAP were lower in patients with PAD (ABI <0.9) than in patients without PAD (ABI >0.9) (P < 0.001). After multiple regression analysis, a correlation between AGEs and pentosidine, as independent variables, and ABI, as the dependent variable, was found in both patients with and without PAD (r = 0.9198, P < 0.001 and r = 0.5764, P < 0.001, respectively) but not in control subjects. When individual regression coefficients were evaluated, only that due to pentosidine was confirmed as significant. For patients with PAD, considering TRAP, vitamin E, and MDA as independent variables and ABI as the dependent variable produced an overall significant regression (r = 0.6913, P < 0.001). The regression coefficients for TRAP and vitamin E were not significant, indicating that the model is best explained by a single linear regression between MDA and ABI. These findings were also confirmed by principal component analysis.

CONCLUSIONS—Results show that pentosidine and MDA are strongly associated with PAD in type 2 diabetic patients.

Abbreviations: ABI, ankle-brachial index • AGE, advanced glycation end product • FPG, fasting plasma glucose • LC, liquid chromatography • MDA, malondialdehyde • PAD, peripheral artery disease • PCA, principal component analysis • R-PE, R-phycoerythrin • TRAP, total reactive antioxidant potential

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S.-Y. Goh and M. E. Cooper The Role of Advanced Glycation End Products in Progression and Complications of Diabetes J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1143 - 1152. [Abstract] [Full Text] [PDF]